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FIGURE 4. The abrupt rise in BP is associated with calcium chloride 
therapy just before reperfusion of the new liver. Reperfusion is associ-
ated with a drop in BP and filling pressures, but no rise in IVCP 
pressure, suggesting myocardial depression and/or hemorrhage as etiol-
ogies, rather than impaired venous return. Time, in minutes, is indi-
cated by the vertical marks on the dark horizontal line at the bottom 
of the CVP tracing. (HR) heart rate; (BP) blood pressure; (PAl pul-
monary artery; (CVP) central venous pressure; (ETC02) end-tidal 
carbon dioxide; (lCVP) inferior vena ca,,'a pressure. 
TABLE 2. Relative magnitude of Clinical Events on Measured 
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" Width of arrow shaft indicates relative magnitude of event on meas-
ured pressure. - indicates no effect; GRAD, IVCP - CUP. 
rhage, all common occurrences during OLT. Increases in IVCP 
suggest the former two problems as a cause, and dictate me-
chanical (rather than pharmacologic) fluid or blood product 
therapy. (Table 2). It is intuitive that maximizing VVB pump 
flows should lead to higher VR, CO and blood pressure as well, 
while minimizing the gradient to venous return. Finally, it is 
possible to assess the quality of vena caval anastomosis since 
normal flow should yield a low gradient. 
We conclude that IVCP and the gradient to venous return 
are simple to measure and that knowledge of acute and chronic 
trends provides valuable adjunctive hemodynamic information 
during OLT. 
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LIVER TRANSPLAJI.;"TATION IN PATIENTS WITH LANGERHANS' CELL HISTIOCYTOSIS! 
Langerhans' cell histiocytosis (LCH)* is an uncommon dis-
ease, characterized by an abnormal proliferation of histiocytic 
cells of the dendritic family. Some patients with systemic LCH 
have primary liver involvement that may resemble sclerosing 
! This work was supported by resean:h grants from the Veterans 
Administration and by Project Grant AM 29961 from the National 
Institutes of Health, Bethesda, MO. 
• Abbreviation: LCH, Langerhana' cen hystiocyt.ollis. 
cholangitis. Others may develop end-stage liver disease as a 
result of the chemotherapeutic agents used to control the 
primary disorder. We have performed liver transplantation in 
two children and one adult with this disease, the largest single-
center experience in the world. A follow-up of these cases may 
be of special interest for two reasons. YInt, perturbations in 
the immune system are common in this disease. Second, light 
can be shed on whether immunosuppression can influence a 
disease with a possible autoimmune etiology. 
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Two children and one adult with a history of LCH underwent 
orthotopic liver transplantation at the University o( Pittsburgh 
since 1984. As noted, the diagnosis of the disease preceded their 
end-stage liver disease by 5-15 years. All three bad received 
some form of chemotherapy that succeeded in controlling the 
active disease. In two of the patients (RW. and H.C.), the end-
stage liver disease was a direct result of the LCH. In the third 
patient (G.C.), the cirrhosis was the result of the chemotherapy 
treatment with methotrexate. The LCH seemed to be in com-
plete remission at the time of the transplantation in the two 
pediatric cases, but appeared to be still active, at least in the 
liver (by histology) in the adult case. 
No tissue from pretransplant pathological studies was avail-
able to us at the time of the preoperative evaluation. The 
patients were referred to us with a diagnosis of LCH that had 
been previously established in other centers. The first pediatric 
patient (RW.), was initially diagnosed with an eosinophilic 
granuloma of the skull. Subsequently he had skin in.olvement, 
with Langerhans' cell infiltration. At the age of 6 years, he also 
developed diabetes insipidus. The adult patient (H.C.) was 
diagnosed as having LCH on the basis of an open-lung biopsy. 
There is no evidence that the immunological markers were 
searched for. Multiple intrahepatic masses by CT scan were 
interpreted as LCH. The removed livers were thoroughly ex-
amined for the presence of the typical Langerhans cells (below) 
with hematoxyilin-eosin staining as well as staining for tbe 
characteristic surface markers. 
The hilar areas and peripheral sections of the resected livers 
were searched for evidence of LCH. Only the adult specimen 
contained histiocytes that stained positively (or the 5-100 pro-
tein, and all the specimens were negative (or clusters of ovoid 
cells bearing class II T6 surface antigen markers. 
All three patients underwent orthotopic liver transplantation 
according to a technique amply described (1). One o( the 
children required two retransplants due to repeated episodes of 
rejection. All three received the standard immunosuppressive 
regimen in place at the time at the University of Pittsburgh, 
based on cyclosporine (Sandimmune) and steroids. Rejection 
was treated with either a temporary increase of the steroid 
doses or with the antithymocyte monoclonal antibody prepa-
ration OKT3 (Orthoclone). Small doses of azathioprine (lmu-
ran) were added as needed for persistent low-grade rejection. 
All three patients did well intraoperatively and sunived for 
at least 1 year. The adult patient died 14 months after his 
transplant from pulmonary embolism following a trsumatic 
long bone fracture. The two pediatric patients are still alive, 5 
and e~ years later. There is no evidence of recurrence of LCH 
in the pediatric patients. In the adult patient, there was no 
clinical evidence of recurrence of the disorder at the time of his 
death. Unfortunately, the family denied permission for autopsy, 
10 no tissue was available for analysis. All three patients had 
repeated episodes of acute cellular rejection. The first child 
liven a transplant by us necessitated two retransplants, both 
because of uncontrollable rejection. All three patients required 
treatment with OKT3, two of them more than once. 
Langerhans' cell histiocytosis, previously known as histio-
cytosis X2, is a term that covers a range of disorders character-
ized by abnormal proliferation of Langerhans' histiocytic cella 
(3). Terms such as histiocytosis merely describe histological 
findings, and do not clarify the confusion that still reigns in 
defining the etiology and pathogenesis of these disorders (3). 
The classic Letterer-Siwe (4, 5) and Hand-Schuller-Christian 
(6,7) diseases and the eosinophilic granuloma of the bone were 
integrated into a single entity by the landmark research of 
Lichtenstein in 1953 (8). The etiology of the disorder is still 
unclear, although immunologic (and possibly autoimmunologic) 
mechanisms obviously play a role. Several hypotheses have 
been advanced regarding the pathogenesis of LCH (3). The 
characteristic Langerhans' cells are dendritic cells usually 
found in the skin where they act as antigen-presenting cells (9) 
in a different way from monocytes and macrophages (10). 
These cells contain the S-1OO protein (11), a calmodulin-like 
substance and have characteristic surface antigen markers. The 
Ia antigen is coded for by the HLA-DR locus (12). Its expres-
sion is not influenced by microbial or lymphokine stimulation, 
as in macrophages (13). The T6 surface antigen may also be 
present on the surface membrane of the Langerhans' cell; its 
significance remains unclear (11). Intracytoplasmatic organ-
elles called "Birbeck granules" are characteristic of these cells 
but their significance is unclear (14). The majority of patients 
are of pediatric age, although LCH has been described in adults. 
It is not known what causes the histiocytes to proliferate 
abnormally and infiltrate a variety of organs and sites. The 
protean nature of the disorder is evidenced by the variability 
of infiltration sites. When the involvement is in one place 
(bony or nonbony), the term eosinophilic granuloma may be 
used. Multifocal involvement produces the eponymous syn-
dromes (Hand-Schuller-Christian or Letterer-Siwe disease). 
The infiltrates of histiocytes may produce "punched-out" 
lesions of the skull, vertebrae, and other bones (15, 16). Hy-
pothalamic involvement occurs with diabetes insipidus in 25-
50% of the patients (17). Extensive invasion of lymph nodes, 
spleen, and liver is relatively common (18-20). Bone marrow 
involvement, especially with thrombocytopenia (21) is partic-
ularly ominous. The hepatic involvement can range from mild 
cholestasis to progressively more severe pictures of histiocytic 
infiltration and bile duct involvement-and, ultimately, scle-
rosing cholangitis (22, 23). In fact, the last can eventually lead 
to severe fibrosis and liver failure (24,25). Primary sclerosing 
cholangitis has been described as associated with LCH in adults 
(26) and in up to 15% of the pediatric cases (27). The severity 
and prognosis of the disease is determined by the age of onset, 
extent of organ infiltration, number of involved sites, and 
rapidity of the progression of lesions. Staging of the disorder 
has been used for prognostic and therapeutic purposes (3). 
Although not classified as a malignancy (28), LCH has many 
elements in common with malignant lymphomas, especially the 
abnormal cellular proliferation and the immunologic changes 
(11, 29-32), especially thymic (33, 34) and immunoglobulin 
(35) abnormalities. A suppressor T cell deficiency seems to be 
characteristic of the disease (36, 37). 
LCH is a relatively infrequent disease that usually has a 
relatively benign course, particularly if appropriately treated. 
Local radiation therapy, steroids, chemotherapeutic agents-
and, more recently, immunotherapy have been the treatment 
modalities most widely used (38-41). However, chemotherapy 
administered for diffuse histiocytic lesions, especially metho-
trexate, may result in irreversible toxic liver damage (11). 
The relative decrease in the number of T suppressor cells in 
LCH may, in part, explain the severity and/or frequency of 
rejection that we observed in our patients. Unfortunately, the 
T4/T8 ratio is not routinely measured in our transplant popu-
lation, either pre- or postoperatively, so this can be construed 
as mere speculation. Also, it is not clear whether successful 
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treatment of the syndrome results into a restoration of the 
immunological parameters (including the T4(fS ratio) to nor-
mal. although there is some preliminary evidence that this may 
occur with immunotherapy. Whether LCH itself or the therapy 
previously administered to treat it (in particular, immunother-
apy) predisposes to rejection more severe than normally ex-
pected can only be answered by better monitoring in the few 
cases that exist. 
On the other hand. there has been no recurrence of the 
disease in our two living patients after up to 5 years of follow-
up. As immunosuppressive drugs. including cyclosporine are a 
part of the usual armamentarium in the treatment of LCH. it 
is possible that the posttransplant immunosuppression may 
prevent recurrence. Although the number of patients is very 
small and the follow up relatively brief. the absence of recur-
rence is encouraging and leads us to believe that liver trans-
plantation may be indicated for end-stage liver disease associ-
ated with LCH. 
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